Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Current Assets (2017 - 2025)

Historic Current Assets for Aclaris Therapeutics (ACRS) over the last 9 years, with Q3 2025 value amounting to $100.6 million.

  • Aclaris Therapeutics' Current Assets fell 2398.4% to $100.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $100.6 million, marking a year-over-year decrease of 2398.4%. This contributed to the annual value of $126.0 million for FY2024, which is 225.45% down from last year.
  • Aclaris Therapeutics' Current Assets amounted to $100.6 million in Q3 2025, which was down 2398.4% from $104.2 million recorded in Q2 2025.
  • Over the past 5 years, Aclaris Therapeutics' Current Assets peaked at $259.4 million during Q2 2022, and registered a low of $100.6 million during Q3 2025.
  • Over the past 5 years, Aclaris Therapeutics' median Current Assets value was $134.5 million (recorded in 2021), while the average stood at $164.2 million.
  • Its Current Assets has fluctuated over the past 5 years, first surged by 25662.08% in 2021, then tumbled by 5203.39% in 2023.
  • Aclaris Therapeutics' Current Assets (Quarter) stood at $205.0 million in 2021, then grew by 12.93% to $231.6 million in 2022, then tumbled by 44.35% to $128.9 million in 2023, then fell by 2.25% to $126.0 million in 2024, then decreased by 20.13% to $100.6 million in 2025.
  • Its last three reported values are $100.6 million in Q3 2025, $104.2 million for Q2 2025, and $108.8 million during Q1 2025.